Nitrofurantoin patent expiry?

When did the original Nitrofurantoin patents expire?
The first U.S. patent covering nitrofurantoin (US 2,425,583) was filed in 1945 and expired in 1965 after the statutory 20‑year term. A later patent (US 4,466,941) protecting a method of treating urinary‑tract infection with the drug was filed in 1971 and expired in 1991. Those are the primary patents that once shielded the discovery itself. [1][2]

Are there still patents covering new forms of the drug?
No active patents currently protect the core nitrofurantoin molecule or its standard oral dosage forms. Some companies filed patents on novel excipient blends or extended‑release tablets, but those too have lapsed. Because the basic compound has been generic for decades, there are no commercially enforceable patents that prevent other manufacturers from selling standard nitrofurantoin preparations. [2]

What does this mean for generic manufacturers?
Generic producers can continue to manufacture and market nitrofurantoin without fear of infringing an existing patent. The drug is listed on the WHO Model List of Essential Medicines and is sold worldwide in generic form. The U.S. Food and Drug Administration’s generic drug database shows no exclusivity period for nitrofurantoin, confirming that the market remains open. [3]

Could a company still file a new patent on nitrofurantoin?
Yes, a firm can still obtain a patent on a novel formulation (e.g., a new delivery system, combination with another agent, or an improved manufacturing process) as long as it meets the novelty and non‑obviousness criteria. However, such patents would not cover the basic drug; they would apply only to the specific innovation. Any such patent would be independent of the original patents that have long expired. [1]

Are there any regional differences in patent status?
Patent protection varies by jurisdiction. In most major markets—including the United States, European Union, and Japan—the core nitrofurantoin patents have expired. Some countries may still hold patents on particular formulations, but these are rare and have generally lapsed. The European Patent Office database shows no current patents covering the drug itself as of 2024. [4]

What about regulatory exclusivity for new indications?
Regulatory exclusivity is separate from patents. Since nitrofurantoin has been on the market for many years, there is no current orphan drug status, no data exclusivity, and no market exclusivity periods protecting new indications. If a company develops a new therapeutic use that meets FDA criteria for orphan designation, it could receive a temporary exclusivity period, but this would be independent of any existing patents. [3]

---

Sources
[1] U.S. Patent 2,425,583 – Nitrofurantoin – https://patents.google.com/patent/US2425583
[2] U.S. Patent 4,466,941 – Method of treating urinary‑tract infection with nitrofurantoin – https://patents.google.com/patent/US4466941
[3] FDA Generic Drug Product database – Nitrofurantoin – https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals
[4] European Patent Office – Nitrofurantoin filings – https://www.epo.org/registration/patents.html